These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10808195)

  • 41. Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer.
    Ozen H; Aygün C; Ergen A; Sözen S; Aki FT; Uygur MC
    Am J Clin Oncol; 2001 Dec; 24(6):610-3. PubMed ID: 11801765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges.
    Meshref AW; Bazinet M; Trudel C; Aronson S; Peloquin F; Nachabe M; Dessureault J; Aprikian AG; Begin LR; Elhilali MM
    Urology; 1995 Jun; 45(6):972-9. PubMed ID: 7539562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
    Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy.
    Coetzee LJ; Hars V; Paulson DF
    Urology; 1996 Feb; 47(2):232-5. PubMed ID: 8607240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM; García Morata F; Villamón Fort R; Pastor Hernández F; Gil Salom M; García Sisamón F
    Actas Urol Esp; 2003 Jun; 27(6):442-9. PubMed ID: 12918151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate cancer detection in candidates for open prostatectomy.
    Fowler JE; Bigler SA; Kolski JM
    J Urol; 1998 Dec; 160(6 Pt 1):2107-10. PubMed ID: 9817333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
    Partin AW; Carter HB
    Urol Clin North Am; 1996 Nov; 23(4):531-40. PubMed ID: 8948408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 1994 May; 151(5):1283-90. PubMed ID: 7512659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.